$FEMY
FEMASYS INC

2023 Q2 Form 10-Q Financial Statement

#000114036123024144 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $320.5K $294.0K $321.4K
YoY Change 5.74% -8.53% -2.54%
Cost Of Revenue $110.5K $105.1K $122.7K
YoY Change 7.93% -14.31% 31.85%
Gross Profit $210.0K $188.9K $198.7K
YoY Change 4.62% -4.96% -16.05%
Gross Profit Margin 65.53% 64.24% 61.83%
Selling, General & Admin $1.486M $1.560M $1.516M
YoY Change 19.31% 2.89% 65.74%
% of Gross Profit 707.25% 826.01% 762.95%
Research & Development $1.527M $1.537M $1.421M
YoY Change 3.68% 8.19% 42.82%
% of Gross Profit 727.07% 814.05% 715.07%
Depreciation & Amortization $133.3K $131.7K $144.2K
YoY Change -6.57% -8.7% -6.03%
% of Gross Profit 63.47% 69.71% 72.56%
Operating Expenses $3.146M $3.231M $3.081M
YoY Change 9.97% 4.84% 49.35%
Operating Profit -$2.936M -$3.042M -$2.883M
YoY Change 10.38% 5.51% 57.83%
Interest Expense $198.00 $1.672K $2.734K
YoY Change -77.58% -38.84% -28.95%
% of Operating Profit
Other Income/Expense, Net $42.45K $95.42K -$280.00
YoY Change 64.16% -34177.5%
Pretax Income -$2.894M -$2.946M -$2.883M
YoY Change 9.85% 2.19% 57.52%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.894M -$2.946M -$2.883M
YoY Change 9.85% 2.19% 57.52%
Net Earnings / Revenue -902.77% -1002.18% -897.01%
Basic Earnings Per Share -$0.22 -$0.25 -$0.24
Diluted Earnings Per Share -$0.22 -$0.25 -$0.24
COMMON SHARES
Basic Shares Outstanding 13.19M 11.87M 11.80M
Diluted Shares Outstanding 13.11M 11.87M 11.80M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.71M $10.16M $21.77M
YoY Change -44.0% -53.32% 979.45%
Cash & Equivalents $10.71M $10.16M $21.77M
Short-Term Investments
Other Short-Term Assets $587.8K $542.1K $567.3K
YoY Change -31.25% -4.45% 98.44%
Inventory $581.5K $500.7K $223.0K
Prepaid Expenses
Receivables $155.7K $124.0K $170.3K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $12.03M $11.33M $22.73M
YoY Change -40.82% -50.16% 794.03%
LONG-TERM ASSETS
Property, Plant & Equipment $1.255M $1.378M $2.162M
YoY Change -23.02% -36.27% -18.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $865.6K $920.8K $625.4K
YoY Change 30.54% 47.23% -56.73%
Total Long-Term Assets $2.284M $2.540M $2.805M
YoY Change -18.18% -9.46% -32.31%
TOTAL ASSETS
Total Short-Term Assets $12.03M $11.33M $22.73M
Total Long-Term Assets $2.284M $2.540M $2.805M
Total Assets $14.31M $13.87M $25.53M
YoY Change -38.09% -45.69% 281.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $546.9K $526.8K $548.4K
YoY Change 27.68% -3.94% -59.99%
Accrued Expenses $536.8K $535.4K $565.2K
YoY Change -2.72% -5.27% -56.99%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $209.1K $305.1K $446.3K
YoY Change -74.26% -31.64% -63.85%
Total Short-Term Liabilities $1.382M $1.413M $1.632M
YoY Change -25.91% -13.45% -58.7%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $305.1K
YoY Change -100.0% -100.0% -59.4%
Other Long-Term Liabilities $56.25K $98.82K $102.5K
YoY Change -48.46% -3.59% -49.41%
Total Long-Term Liabilities $56.25K $98.82K $407.6K
YoY Change -82.33% -75.75% -57.28%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.382M $1.413M $1.632M
Total Long-Term Liabilities $56.25K $98.82K $407.6K
Total Liabilities $1.438M $1.511M $2.040M
YoY Change -34.14% -25.9% -58.42%
SHAREHOLDERS EQUITY
Retained Earnings -$99.97M -$97.08M
YoY Change 13.28%
Common Stock $15.19K $11.99K
YoY Change 27.32%
Preferred Stock
YoY Change
Treasury Stock (at cost) $60.00K
YoY Change
Treasury Stock Shares $117.2K
Shareholders Equity $12.88M $12.36M $23.49M
YoY Change
Total Liabilities & Shareholders Equity $14.31M $13.87M $25.53M
YoY Change -38.09% -45.69% 281.88%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$2.894M -$2.946M -$2.883M
YoY Change 9.85% 2.19% 57.52%
Depreciation, Depletion And Amortization $133.3K $131.7K $144.2K
YoY Change -6.57% -8.7% -6.03%
Cash From Operating Activities -$2.741M -$2.648M -$2.754M
YoY Change 15.18% -3.86% 137.28%
INVESTING ACTIVITIES
Capital Expenditures $62.95K $8.901K -$120.4K
YoY Change -136.04% -107.39%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$62.95K -$8.901K -$120.4K
YoY Change -63.96% -92.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.348M -144.1K -141.0K
YoY Change -3563.85% 2.16% -2.75%
NET CHANGE
Cash From Operating Activities -2.741M -2.648M -2.754M
Cash From Investing Activities -62.95K -8.901K -120.4K
Cash From Financing Activities 3.348M -144.1K -141.0K
Net Change In Cash 543.7K -2.801M -3.015M
YoY Change -120.51% -7.12% 130.95%
FREE CASH FLOW
Cash From Operating Activities -$2.741M -$2.648M -$2.754M
Capital Expenditures $62.95K $8.901K -$120.4K
Free Cash Flow -$2.804M -$2.657M -$2.634M
YoY Change 27.16% 0.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3373
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2023Q1 us-gaap Treasury Stock Value
TreasuryStockValue
60000
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
60000
CY2022Q1 us-gaap Depreciation
Depreciation
136769
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-91211
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-97851
CY2023Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
2306
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8901
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
120368
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8901
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-120368
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
141298
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-141006
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2800598
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3015395
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10161338
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21767634
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10161338
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2946257
CY2023Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
117223
CY2023Q1 femy Accrued Clinical Trial Cost
AccruedClinicalTrialCost
315428
CY2022Q4 femy Accrued Clinical Trial Cost
AccruedClinicalTrialCost
333440
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
111457
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
85191
CY2023Q1 femy Franchise Taxes
FranchiseTaxes
7100
CY2022Q4 femy Franchise Taxes
FranchiseTaxes
26886
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
101432
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
11197
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
535417
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
456714
CY2022Q4 femy Clinical Holdback Liability
ClinicalHoldbackLiability
141864
CY2023Q1 femy Clinical Holdback Noncurrent
ClinicalHoldbackNoncurrent
98818
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001339005
CY2022Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
117223
CY2023Q1 us-gaap Gross Profit
GrossProfit
188864
CY2022Q1 us-gaap Gross Profit
GrossProfit
198730
CY2023Q1 us-gaap Interest Expense
InterestExpense
1672
CY2022Q1 us-gaap Interest Expense
InterestExpense
2734
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
95417
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-280
CY2023Q1 femy Stock Issued During Period Value At The Market Offering Net Of Issuance Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingNetOfIssuanceCosts
3368
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2946257
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2946257
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2883030
CY2023Q1 us-gaap Depreciation
Depreciation
131653
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1413
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
7430
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
75635
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
86233
CY2023Q1 us-gaap Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
300
CY2022Q1 us-gaap Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
2700
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
56954
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
44359
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
46485
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
86044
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
64318
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
17438
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-150654
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-18553
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3016
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
102855
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
78703
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-38559
CY2022Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-29998
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2647637
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2754021
CY2022Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
135457
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
6135
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
5549
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-144060
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12961936
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24783029
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
1672
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
2734
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11804165
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
800
CY2023Q1 femy Property And Equipment Costs Included In Accounts Payable
PropertyAndEquipmentCostsIncludedInAccountsPayable
12990
CY2022Q1 femy Property And Equipment Costs Included In Accounts Payable
PropertyAndEquipmentCostsIncludedInAccountsPayable
0
CY2023Q1 femy Commissions And Deferred Offering Costs Relating To Proceeds From Issuance Of Common Stock
CommissionsAndDeferredOfferingCostsRelatingToProceedsFromIssuanceOfCommonStock
109
CY2022Q1 femy Commissions And Deferred Offering Costs Relating To Proceeds From Issuance Of Common Stock
CommissionsAndDeferredOfferingCostsRelatingToProceedsFromIssuanceOfCommonStock
0
CY2023Q1 femy Prepaid Insurance Financed With Promissory Note
PrepaidInsuranceFinancedWithPromissoryNote
0
CY2022Q1 femy Prepaid Insurance Financed With Promissory Note
PrepaidInsuranceFinancedWithPromissoryNote
45666
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-97080762
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
283655
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
244498
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
98775
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
100453
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
118311
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
91772
CY2023Q1 us-gaap Inventory Net
InventoryNet
500741
CY2022Q4 us-gaap Inventory Net
InventoryNet
436723
CY2023Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2380
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2103
CY2023Q1 femy Clinical Holdback Retained
ClinicalHoldbackRetained
2634
CY2023Q1 femy Clinical Holdback Paid
ClinicalHoldbackPaid
328
CY2023Q1 femy Clinical Holdback Liability
ClinicalHoldbackLiability
144170
CY2023Q1 femy Clinical Holdback Current
ClinicalHoldbackCurrent
45352
CY2022Q1 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
CY2023Q1 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
CY2023Q1 femy Percentage Of Restocking Fee
PercentageOfRestockingFee
0.30
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11872255
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11872573
CY2023Q1 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
56954
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
44359
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
926280
CY2023Q1 femy Share Based Compensation Expense To Be Recognized Upon Achieving Certain Performance Condition
ShareBasedCompensationExpenseToBeRecognizedUponAchievingCertainPerformanceCondition
463311
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
462969
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2946257
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2946257
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2883030
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2883030
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11872255
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11804165
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2023Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1036495
CY2022Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1055997
CY2023Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
233460
CY2022Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
244572
CY2023Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1269955
CY2022Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1300569

Files In Submission

Name View Source Status
0001140361-23-024144-index-headers.html Edgar Link pending
0001140361-23-024144-index.html Edgar Link pending
0001140361-23-024144.txt Edgar Link pending
0001140361-23-024144-xbrl.zip Edgar Link pending
brhc20052573_10q.htm Edgar Link pending
brhc20052573_ex31-1.htm Edgar Link pending
brhc20052573_ex31-2.htm Edgar Link pending
brhc20052573_ex32-1.htm Edgar Link pending
brhc20052573_ex32-2.htm Edgar Link pending
femy-20230331.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
femy-20230331_def.xml Edgar Link unprocessable
femy-20230331_cal.xml Edgar Link unprocessable
femy-20230331_lab.xml Edgar Link unprocessable
femy-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
brhc20052573_10q_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending